Iovance Biotherapeutics, Inc. Common Stock IOVA
$14.21
-2.00%
at last close
Analyst Consensus
- Consensus Rating
- Buy (8 Buy · 2 Hold · 0 Sell)
- Average Price Target
- $13.20
- Implied Upside
- -7.1%
- Price Target Range
- $7.00 – $20.00
- Analysts (12 mo)
- 10
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-10-13 | BarclaysEtzer Darout |
Maintains | Overweight | $15 → $18 |
| 2026-10-08 | BairdColleen Kusy |
Maintains | Neutral | $6 → $11 |
| 2026-09-30 | Wells FargoYanan Zhu |
Maintains | Overweight | $14 → $18 |
| 2026-09-29 | HC Wainwright & Co.Joseph Pantginis |
Maintains | Buy | $9 → $20 |
| 2026-09-24 | Goldman SachsAndrea Newkirk |
Reinstates | Buy | $15 |
| 2026-09-17 | BarclaysEtzer Darout |
Maintains | Overweight | $13 → $15 |
| 2026-08-25 | TD CowenNicholas Lorusso |
Maintains | Buy | $7 → $10 |
| 2026-08-20 | UBSDavid Dai |
Maintains | Neutral | $4 → $7 |
| 2026-08-18 | MizuhoMara Goldstein |
Maintains | Outperform | $10 → $11 |
| 2026-08-07 | BarclaysEtzer Darout |
Maintains | Overweight | $11 → $13 |
| 2026-08-07 | CitizensReni J. Benjamin |
Maintains | Market outperform | $5 → $8 |
| 2026-05-07 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $16 → $14 |
| 2026-04-10 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $16 |
| 2026-03-05 | UBSDavid Dai |
Maintains | Neutral | $2 → $4 |
| 2026-03-03 | CitizensReni J. Benjamin |
Upgrades | Market perform → Market outperform | $5 |
| 2026-02-25 | BarclaysEtzer Darout |
Maintains | Overweight | $10 → $11 |
| 2026-02-25 | CitizensReni J. Benjamin |
Upgrades | Market perform → Market outperform | $5 |
| 2025-12-17 | BarclaysEtzer Darout |
Maintains | Overweight | $9 → $10 |
| 2025-11-24 | BarclaysEtzer Darout |
Maintains | Overweight | $4 → $9 |
| 2025-11-06 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $20 → $17 |
| 2025-10-29 | HC Wainwright & Co.Joseph Pantginis |
Maintains | Buy | $20 → $9 |
| 2025-08-19 | HC Wainwright & Co.Joseph Pantginis |
Reiterates | Buy | $20 |
| 2025-08-08 | Wells FargoYanan Zhu |
Maintains | Overweight | $18 → $14 |
| 2025-08-08 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $25 → $20 |
| 2025-07-23 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $25 |
| 2025-05-16 | UBSDavid Dai |
Downgrades | Buy → Neutral | $17 → $2 |
| 2025-05-12 | Goldman SachsAndrea Tan |
Maintains | Buy | $16 → $8 |
| 2025-05-12 | MizuhoMara Goldstein |
Maintains | Outperform | $30 → $10 |
| 2025-05-12 | BarclaysPeter Lawson |
Maintains | Overweight | $5 → $4 |
| 2025-05-09 | JMP SecuritiesReni Benjamin |
Downgrades | Market outperform → Market perform | — |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $14.21
- Market Cap
- $6.57 billion
- 52-Week Range
- $1.76 – $15.30
- Average Volume
- 16.81 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.